Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ACP3 | P15309 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30061063 | 1.00 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL545865 | 1.00 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL1134287 | 1.00 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL2168922 | 1.00 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL17530049 | 1.00 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL17530048 | 1.00 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28444128 | 0.98 | SIGMAR1 (0.71) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2427692 | 0.98 | SIGMAR1 (0.71) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2427690 | 0.98 | SIGMAR1 (0.71) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28444130 | 0.98 | SIGMAR1 (0.71) | SIGMAR1KMT2AMEN1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017803-B2 | Process for the preparation of tamsulosin and intermediates thereof | HOVIONE INTER LTD. (CH) | 2011-09-13 | — | — | US | claimed |
| US-20090234154-A1 | Process for the preparation of tamsulosin and intermediates thereof | HOVIONE INTER LTD. | 2009-09-17 | — | — | US | claimed |
| EP-1828110-B1 | PROCESS FOR THE PREPARATION OF TAMSULOSIN AND INTERMEDIATES THEREOF | HOVIONE INTER AG (CH) | 2009-04-08 | — | — | EP | claimed |
| CN-111170900-B | Preparation method of tamsulosin impurity with high optical purity | 珠海润都制药股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-111170900-A | Preparation method of tamsulosin impurity with high optical purity | 珠海润都制药股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-109879764-A | A kind of method that low cost prepares doxazosin-mesylate controlled-releasing tablet | 陕西修风生物科技有限公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-106631918-B | The method for splitting Tamsulosin enantiomter | 深圳万和制药有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-106478467-B | The method for preparing stable tamsulosin hydrochloride | 深圳万和制药有限公司 | 2018-07-13 | — | — | CN | disclosed |
| EP-2305635-B1 | FORMOTEROL TARTRATE, PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| CN-106631918-A | Method of resolving tamsulosin enantiomer | 深圳万和制药有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106478467-A | The method for preparing stable tamsulosin hydrochloride | 深圳万和制药有限公司 | 2017-03-08 | — | — | CN | disclosed |
| EP-1082293-B1 | FORMOTEROL POLYMORPHS | SEPRACOR INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030149304-A1 | Formoterol tartrate polymorph | SEPRACOR INC. | 2003-08-07 | — | — | US | disclosed |
| EP-1093450-B1 | DESFORMOTEROL AND PROCESS FOR ITS PREPARATION | SEPRACOR INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6472563-B1 | RECRYSTALLIZATION FROM AQUEOUS ISOPROPYL ALCOHOL; HIGH PURITY; THERMODYNAMICALLY STABLE | SEPRACOR INC. | 2002-10-29 | — | — | US | disclosed |
| EP-0938467-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6268533-B1 | REACTING 4-BENZYLOXY-3-FORMAMIDOSTYRENE OXIDE WITH AN OPTICALLY PURE 4-METHOXY-.ALPHA.-METHYL-N-(PHENYLMETHYL)BENZENEETHANAMINE FOLLOWED BY REDUCTION TO PRODUCE FORMOTEROL | SEPRACOR INC. | 2001-07-31 | — | — | US | disclosed |
| US-6071971-A | FOR TREATING PULMONARY DISORDERS | SEPRACOR INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6040344-A | CRYSTALLINE R,R-FORMOTEROL L-(+)-TARTRATE. | SEPRACOR INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5965622-A | BRONCHODILATORS; HIGHLY SELECTIVE BETA 2-ADRENERGIC RECEPTOR AGONIST; RESPIRATORY DISORDERS, E.G. ASTHMA, BRONCHITIS; REDUCTION OF A PROTECTED NITRO DERIVATIVE; STEREOSPECIFIC | SEPRACOR INC. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149304-A1 | Formoterol tartrate polymorph | ADRB1, ADRA1B, ADRA1A | SIGMAR1 798/4885KMT2A 4777/4885MEN1 4373/4885 |
| US-20090234154-A1 | Process for the preparation of tamsulosin and intermediates thereof | AVPR2, AVPR1B, TACR2 | SIGMAR1 315/4885KMT2A 3421/4885MEN1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.